Physician profile
Carl E Mclemore
NPI 1073513941
$8,813.08
in general payments reported to CMS, 2019-2025
47 companies · $1,538 in 2025
The $1,538 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,145 · 2020: $832 · 2021: $905 · 2022: $1,744 · 2023: $1,288 · 2024: $1,360 · 2025: $1,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,166 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,165.84 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,182.46 | 2021-2025 | |
| Novo Nordisk INC | $917.39 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $820.92 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Ironshore Pharmaceuticals INC. | $458.69 | 2019-2024 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $447.61 | 2019-2025 | Jardiance |
| Pfizer INC. | $415.96 | 2019-2025 | |
| Amgen INC. | $361.36 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $319.81 | 2022-2025 | |
| Abbott Laboratories | $312.23 | 2022-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $311.32 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $305.62 | 2019-2023 | Trintellix |
| Glaxosmithkline, LLC. | $283.44 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $256.86 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $201.91 | 2022-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $191.15 | 2020-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Mclemore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.